Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Last Name

profilePaul B. Yu, Ph.D., M.D.

TitleAssociate Professor of Medicine
InstitutionBrigham and Women's Hospital
AddressBrigham and Women's Hospital
Thorn 1203A
75 Francis St
Boston MA 02115
vCardDownload vCard (login for email)

Collapse Biography 
Collapse awards and honors
2005 - 2007GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease Young Investigator
2006 - 2011Pulmonary Hypertension Association Mentored Clinical Scientist Award
2008 - 2013Howard Hughes Medical Institute Physician Scientist Early Career Award
2008 - 2009Massachusetts Technology Transfer Center Investigation Award
2009 - 2011Harvard Stem Cell Institute Seed Grant
2010 - 2015Fondation Leducq Transatlantic Network Award

Collapse Research 
Collapse research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
R01HL131910     (YU, PAUL B)Jul 15, 2016 - Apr 30, 2019
Molecular imaging of angiogenic activity in pulmonary arterial hypertension
Role: Principal Investigator

R01AR057374     (YU, PAUL B)Aug 1, 2010 - Jun 30, 2015
Molecular and cellular mechanisms of heterotopic ossification
Role: Principal Investigator

K08HL079943     (YU, PAUL B)Apr 1, 2006 - Mar 31, 2012
The role of the BMP type II receptor in vascular function
Role: Principal Investigator

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Alessi Wolken DM, Idone V, Hatsell SJ, Yu PB, Economides AN. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva. Bone. 2017 Jun 16. PMID: 28629737.
    View in: PubMed
  2. Dey D, Wheatley BM, Cholok D, Agarwal S, Yu PB, Levi B, Davis TA. The traumatic bone: trauma-induced heterotopic ossification. Transl Res. 2017 Jun 15. PMID: 28668522.
    View in: PubMed
  3. DuBrock HM, Rodriguez-Lopez JM, LeVarge BL, Curry MP, VanderLaan PA, Zsengeller ZK, Pernicone E, Preston IR, Yu PB, Nikolic I, Xu D, Thadhani RI, Channick RN, Ananth Karumanchi S. Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension. Pulm Circ. 2016 Dec; 6(4):498-507. PMID: 28090291.
    View in: PubMed
  4. Dey D, Bagarova J, Hatsell SJ, Armstrong KA, Huang L, Ermann J, Vonner AJ, Shen Y, Mohedas AH, Lee A, Eekhoff EM, van Schie A, Demay MB, Keller C, Wagers AJ, Economides AN, Yu PB. Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification. Sci Transl Med. 2016 Nov 23; 8(366):366ra163. PMID: 27881824.
    View in: PubMed
  5. Yung LM, Nikolic I, Paskin-Flerlage SD, Pearsall RS, Kumar R, Yu PB. A Selective Transforming Growth Factor-ß Ligand Trap Attenuates Pulmonary Hypertension. Am J Respir Crit Care Med. 2016 Nov 01; 194(9):1140-1151. PMID: 27115515.
    View in: PubMed
  6. Szulcek R, Happé CM, Rol N, Fontijn RD, Dickhoff C, Hartemink KJ, Grünberg K, Tu L, Timens W, Nossent GD, Paul MA, Leyen TA, Horrevoets AJ, de Man FS, Guignabert C, Yu PB, Vonk-Noordegraaf A, van Nieuw Amerongen GP, Bogaard HJ. Delayed Microvascular Shear Adaptation in Pulmonary Arterial Hypertension. Role of Platelet Endothelial Cell Adhesion Molecule-1 Cleavage. Am J Respir Crit Care Med. 2016 Jun 15; 193(12):1410-20. PMID: 26760925.
    View in: PubMed
  7. O'Rourke C, Shelton G, Hutcheson JD, Burke MF, Martyn T, Thayer TE, Shakartzi HR, Buswell MD, Tainsh RE, Yu B, Bagchi A, Rhee DK, Wu C, Derwall M, Buys ES, Yu PB, Bloch KD, Aikawa E, Bloch DB, Malhotra R. Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation. J Vis Exp. 2016 May 31; (111). PMID: 27284788.
    View in: PubMed
  8. Nikolic I, Yu PB. The Role of Bone Marrow-derived Cells in Pulmonary Arterial Hypertension. What Lies Beneath? Am J Respir Crit Care Med. 2016 Apr 15; 193(8):822-4. PMID: 27082534; PMCID: PMC4849182 [Available on 04/15/17].
  9. Aghamohammadzadeh R, Zhang YY, Stephens TE, Arons E, Zaman P, Polach KJ, Matar M, Yung LM, Yu PB, Bowman FP, Opotowsky AR, Waxman AB, Loscalzo J, Leopold JA, Maron BA. Up-regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension. FASEB J. 2016 Jul; 30(7):2511-27. PMID: 27006450; PMCID: PMC4904292 [Available on 07/01/17].
  10. Parikh VN, Park J, Nikolic I, Channick R, Yu PB, De Marco T, Hsue PY, Chan SY. Brief Report: Coordinated Modulation of Circulating miR-21 in HIV, HIV-Associated Pulmonary Arterial Hypertension, and HIV/Hepatitis C Virus Coinfection. J Acquir Immune Defic Syndr. 2015 Nov 01; 70(3):236-41. PMID: 26473639; PMCID: PMC4610144 [Available on 11/01/16].
  11. Morrell NW, Bloch DB, ten Dijke P, Goumans MJ, Hata A, Smith J, Yu PB, Bloch KD. Targeting BMP signalling in cardiovascular disease and anaemia. Nat Rev Cardiol. 2016 Feb; 13(2):106-20. PMID: 26461965; PMCID: PMC4886232.
  12. Wang A, Zsengellér ZK, Hecht JL, Buccafusca R, Burke SD, Rajakumar A, Weingart E, Yu PB, Salahuddin S, Karumanchi SA. Excess placental secreted frizzled-related protein 1 in maternal smokers impairs fetal growth. J Clin Invest. 2015 Nov 02; 125(11):4021-5. PMID: 26413870; PMCID: PMC4639969.
  13. Yung LM, Sánchez-Duffhues G, Ten Dijke P, Yu PB. Bone morphogenetic protein 6 and oxidized low-density lipoprotein synergistically recruit osteogenic differentiation in endothelial cells. Cardiovasc Res. 2015 Nov 01; 108(2):278-87. PMID: 26410368; PMCID: PMC4614687 [Available on 11/01/16].
  14. Hatsell SJ, Idone V, Wolken DM, Huang L, Kim HJ, Wang L, Wen X, Nannuru KC, Jimenez J, Xie L, Das N, Makhoul G, Chernomorsky R, D'Ambrosio D, Corpina RA, Schoenherr CJ, Feeley K, Yu PB, Yancopoulos GD, Murphy AJ, Economides AN. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med. 2015 Sep 02; 7(303):303ra137. PMID: 26333933.
    View in: PubMed
  15. Long L, Ormiston ML, Yang X, Southwood M, Gräf S, Machado RD, Mueller M, Kinzel B, Yung LM, Wilkinson JM, Moore SD, Drake KM, Aldred MA, Yu PB, Upton PD, Morrell NW. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med. 2015 Jul; 21(7):777-85. PMID: 26076038; PMCID: PMC4496295.
  16. Chun HJ, Yu PB. Elafin in pulmonary arterial hypertension. Beyond targeting elastases. Am J Respir Crit Care Med. 2015 Jun 01; 191(11):1217-9. PMID: 26029832; PMCID: PMC4476520.
  17. Malhotra R, Burke MF, Martyn T, Shakartzi HR, Thayer TE, O'Rourke C, Li P, Derwall M, Spagnolli E, Kolodziej SA, Hoeft K, Mayeur C, Jiramongkolchai P, Kumar R, Buys ES, Yu PB, Bloch KD, Bloch DB. Inhibition of bone morphogenetic protein signal transduction prevents the medial vascular calcification associated with matrix Gla protein deficiency. PLoS One. 2015; 10(1):e0117098. PMID: 25603410; PMCID: PMC4300181.
  18. Mayeur C, Kolodziej SA, Wang A, Xu X, Lee A, Yu PB, Shen J, Bloch KD, Bloch DB. Oral administration of a bone morphogenetic protein type I receptor inhibitor prevents the development of anemia of inflammation. Haematologica. 2015 Feb; 100(2):e68-71. PMID: 25326432; PMCID: PMC4803128.
  19. Tsugawa D, Oya Y, Masuzaki R, Ray K, Engers DW, Dib M, Do N, Kuramitsu K, Ho K, Frist A, Yu PB, Bloch KD, Lindsley CW, Hopkins CR, Hong CC, Karp SJ. Specific activin receptor-like kinase 3 inhibitors enhance liver regeneration. J Pharmacol Exp Ther. 2014 Dec; 351(3):549-58. PMID: 25271257; PMCID: PMC4244585.
  20. Mohedas AH, Wang Y, Sanvitale CE, Canning P, Choi S, Xing X, Bullock AN, Cuny GD, Yu PB. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 09; 57(19):7900-15. PMID: 25101911; PMCID: PMC4191596.
  21. Zhao Y, Xiao M, Sun B, Zhang Z, Shen T, Duan X, Yu PB, Feng XH, Lin X. C-terminal domain (CTD) small phosphatase-like 2 modulates the canonical bone morphogenetic protein (BMP) signaling and mesenchymal differentiation via Smad dephosphorylation. J Biol Chem. 2014 Sep 19; 289(38):26441-50. PMID: 25100727; PMCID: PMC4176200.
  22. Wu XG, Wang Y, Wu Q, Cheng WH, Liu W, Zhao Y, Mayeur C, Schmidt PJ, Yu PB, Wang F, Xia Y. HFE interacts with the BMP type I receptor ALK3 to regulate hepcidin expression. Blood. 2014 Aug 21; 124(8):1335-43. PMID: 24904118; PMCID: PMC4624447.
  23. Mayeur C, Lohmeyer LK, Leyton P, Kao SM, Pappas AE, Kolodziej SA, Spagnolli E, Yu B, Galdos RL, Yu PB, Peterson RT, Bloch DB, Bloch KD, Steinbicker AU. The type I BMP receptor Alk3 is required for the induction of hepatic hepcidin gene expression by interleukin-6. Blood. 2014 Apr 03; 123(14):2261-8. PMID: 24501215; PMCID: PMC3975261.
  24. Komatsu Y, Yu PB, Kamiya N, Pan H, Fukuda T, Scott GJ, Ray MK, Yamamura K, Mishina Y. Augmentation of Smad-dependent BMP signaling in neural crest cells causes craniosynostosis in mice. J Bone Miner Res. 2013 Jun; 28(6):1422-33. PMID: 23281127; PMCID: PMC3638058.
  25. Sanvitale CE, Kerr G, Chaikuad A, Ramel MC, Mohedas AH, Reichert S, Wang Y, Triffitt JT, Cuny GD, Yu PB, Hill CS, Bullock AN. A new class of small molecule inhibitor of BMP signaling. PLoS One. 2013; 8(4):e62721. PMID: 23646137; PMCID: PMC3639963.
  26. Mohedas AH, Xing X, Armstrong KA, Bullock AN, Cuny GD, Yu PB. Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol. 2013; 8(6):1291-302. PMID: 23547776; PMCID: PMC3901569.
  27. Bagarova J, Vonner AJ, Armstrong KA, Börgermann J, Lai CS, Deng DY, Beppu H, Alfano I, Filippakopoulos P, Morrell NW, Bullock AN, Knaus P, Mishina Y, Yu PB. Constitutively active ALK2 receptor mutants require type II receptor cooperation. Mol Cell Biol. 2013 Jun; 33(12):2413-24. PMID: 23572558; PMCID: PMC3700091.
  28. Malhotra R, Paskin-Flerlage S, Zamanian RT, Zimmerman P, Schmidt JW, Deng DY, Southwood M, Spencer R, Lai CS, Parker W, Channick RN, Morrell NW, Elliott CG, Yu PB. Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension. Pulm Circ. 2013 Apr; 3(2):369-80. PMID: 24015338; PMCID: PMC3757832.
  29. Balboni AL, Hutchinson JA, DeCastro AJ, Cherukuri P, Liby K, Sporn MB, Schwartz GN, Wells WA, Sempere LF, Yu PB, DiRenzo J. ?Np63a-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. Cancer Res. 2013 Jan 15; 73(2):1020-30. PMID: 23243027; PMCID: PMC3739305.
  30. Wu X, Yung LM, Cheng WH, Yu PB, Babitt JL, Lin HY, Xia Y. Hepcidin regulation by BMP signaling in macrophages is lipopolysaccharide dependent. PLoS One. 2012; 7(9):e44622. PMID: 23028567; PMCID: PMC3441567.
  31. Derwall M, Malhotra R, Lai CS, Beppu Y, Aikawa E, Seehra JS, Zapol WM, Bloch KD, Yu PB. Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis. Arterioscler Thromb Vasc Biol. 2012 Mar; 32(3):613-22. PMID: 22223731; PMCID: PMC3679546.
  32. Steinbicker AU, Bartnikas TB, Lohmeyer LK, Leyton P, Mayeur C, Kao SM, Pappas AE, Peterson RT, Bloch DB, Yu PB, Fleming MD, Bloch KD. Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice. Blood. 2011 Oct 13; 118(15):4224-30. PMID: 21841161; PMCID: PMC3204739.
  33. Steinbicker AU, Sachidanandan C, Vonner AJ, Yusuf RZ, Deng DY, Lai CS, Rauwerdink KM, Winn JC, Saez B, Cook CM, Szekely BA, Roy CN, Seehra JS, Cuny GD, Scadden DT, Peterson RT, Bloch KD, Yu PB. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood. 2011 May 05; 117(18):4915-23. PMID: 21393479; PMCID: PMC3100698.
  34. Yeh RW, Yu PB, Drachman DE. Takotsubo cardiomyopathy complicated by cardiac tamponade: classic hemodynamic findings with a new disease. Circulation. 2010 Sep 21; 122(12):1239-41. PMID: 20855670.
    View in: PubMed
  35. Boergermann JH, Kopf J, Yu PB, Knaus P. Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells. Int J Biochem Cell Biol. 2010 Nov; 42(11):1802-7. PMID: 20691279.
    View in: PubMed
  36. Kamiya N, Kobayashi T, Mochida Y, Yu PB, Yamauchi M, Kronenberg HM, Mishina Y. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. J Bone Miner Res. 2010 Feb; 25(2):200-10. PMID: 19874086; PMCID: PMC3153381.
  37. Hong CC, Yu PB. Applications of small molecule BMP inhibitors in physiology and disease. Cytokine Growth Factor Rev. 2009 Oct-Dec; 20(5-6):409-18. PMID: 19914855; PMCID: PMC2813719.
  38. De Rosa L, Antonini D, Ferone G, Russo MT, Yu PB, Han R, Missero C. p63 Suppresses non-epidermal lineage markers in a bone morphogenetic protein-dependent manner via repression of Smad7. J Biol Chem. 2009 Oct 30; 284(44):30574-82. PMID: 19717565; PMCID: PMC2781612.
  39. Wrighton KH, Lin X, Yu PB, Feng XH. Transforming Growth Factor {beta} Can Stimulate Smad1 Phosphorylation Independently of Bone Morphogenic Protein Receptors. J Biol Chem. 2009 Apr 10; 284(15):9755-63. PMID: 19224917; PMCID: PMC2665096.
  40. Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, Bouxsein ML, Hong DW, McManus PM, Katagiri T, Sachidanandan C, Kamiya N, Fukuda T, Mishina Y, Peterson RT, Bloch KD. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med. 2008 Dec; 14(12):1363-9. PMID: 19029982; PMCID: PMC2846458.
  41. Fukuda T, Kohda M, Kanomata K, Nojima J, Nakamura A, Kamizono J, Noguchi Y, Iwakiri K, Kondo T, Kurose J, Endo K, Awakura T, Fukushi J, Nakashima Y, Chiyonobu T, Kawara A, Nishida Y, Wada I, Akita M, Komori T, Nakayama K, Nanba A, Maruki Y, Yoda T, Tomoda H, Yu PB, Shore EM, Kaplan FS, Miyazono K, Matsuoka M, Ikebuchi K, Ohtake A, Oda H, Jimi E, Owan I, Okazaki Y, Katagiri T. Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva. J Biol Chem. 2009 Mar 13; 284(11):7149-56. PMID: 18684712; PMCID: PMC2652274.
  42. Hao J, Daleo MA, Murphy CK, Yu PB, Ho JN, Hu J, Peterson RT, Hatzopoulos AK, Hong CC. Dorsomorphin, a selective small molecule inhibitor of BMP signaling, promotes cardiomyogenesis in embryonic stem cells. PLoS One. 2008 Aug 06; 3(8):e2904. PMID: 18682835; PMCID: PMC2483414.
  43. Cuny GD, Yu PB, Laha JK, Xing X, Liu JF, Lai CS, Deng DY, Sachidanandan C, Bloch KD, Peterson RT. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett. 2008 Aug 01; 18(15):4388-92. PMID: 18621530; PMCID: PMC2570262.
  44. Yu PB, Deng DY, Beppu H, Hong CC, Lai C, Hoyng SA, Kawai N, Bloch KD. Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells. J Biol Chem. 2008 Feb 15; 283(7):3877-88. PMID: 18042551.
    View in: PubMed
  45. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, Lin HY, Bloch KD, Peterson RT. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 2008 Jan; 4(1):33-41. PMID: 18026094; PMCID: PMC2727650.
  46. D'Avila A, Ptaszek LM, Yu PB, Walker JD, Wright C, Noseworthy PA, Myers A, Refaat M, Ruskin JN. Images in cardiovascular medicine. Left atrial-esophageal fistula after pulmonary vein isolation: a cautionary tale. Circulation. 2007 May 01; 115(17):e432-3. PMID: 17470703.
    View in: PubMed
  47. Xia Y, Yu PB, Sidis Y, Beppu H, Bloch KD, Schneyer AL, Lin HY. Repulsive guidance molecule RGMa alters utilization of bone morphogenetic protein (BMP) type II receptors by BMP2 and BMP4. J Biol Chem. 2007 Jun 22; 282(25):18129-40. PMID: 17472960.
    View in: PubMed
  48. Yu PB, Parker W, Nayak JV, Platt JL. Sensitization with xenogeneic tissues alters the heavy chain repertoire of human anti-Galalpha1-3Gal antibodies. Transplantation. 2005 Jul 15; 80(1):102-9. PMID: 16003240.
    View in: PubMed
  49. Yu PB, Beppu H, Kawai N, Li E, Bloch KD. Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells. J Biol Chem. 2005 Jul 01; 280(26):24443-50. PMID: 15883158.
    View in: PubMed
  50. Beppu H, Ichinose F, Kawai N, Jones RC, Yu PB, Zapol WM, Miyazono K, Li E, Bloch KD. BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am J Physiol Lung Cell Mol Physiol. 2004 Dec; 287(6):L1241-7. PMID: 15286002.
    View in: PubMed
  51. Parker W, Stitzenberg KB, Yu PB, Pratt VS, Nakamura YC, Farel LS, Ward CM, Lin SS, Everett ML, Platt JL. Biophysical characteristics of anti-Gal(alpha)1-3Gal IgM binding to cell surfaces: implications for xenotransplantation. Transplantation. 2001 Feb 15; 71(3):440-6. PMID: 11233908.
    View in: PubMed
  52. Gonzalez-Stawinski GV, Yu PB, Love SD, Parker W, Davis RD. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Clin Immunol. 2001 Feb; 98(2):175-9. PMID: 11161973.
    View in: PubMed
  53. Parker W, Lin SS, Yu PB, Sood A, Nakamura YC, Song A, Everett ML, Platt JL. Naturally occurring anti-alpha-galactosyl antibodies: relationship to xenoreactive anti-alpha-galactosyl antibodies. Glycobiology. 1999 Sep; 9(9):865-73. PMID: 10460828.
    View in: PubMed
  54. Yu PB, Parker W, Everett ML, Fox IJ, Platt JL. Immunochemical properties of anti-Gal alpha 1-3Gal antibodies after sensitization with xenogeneic tissues. J Clin Immunol. 1999 Mar; 19(2):116-26. PMID: 10226886.
    View in: PubMed
  55. Parker W, Yu PB, Holzknecht ZE, Lundberg K, Buckley RH, Platt JL. Specificity and function of "natural" antibodies in immunodeficient subjects: clues to B cell lineage and development. J Clin Immunol. 1997 Jul; 17(4):311-21. PMID: 9258770.
    View in: PubMed
  56. Yu PB, Holzknecht ZE, Bruno D, Parker W, Platt JL. Modulation of natural IgM binding and complement activation by natural IgG antibodies: a role for IgG anti-Gal alpha1-3Gal antibodies. J Immunol. 1996 Dec 01; 157(11):5163-8. PMID: 8943428.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at For faculty personal and demographic information, contact HMS Office for Faculty Affairs at
Yu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
Co-Authors Expand Description
Similar People Expand Description
Same Department Expand Description
Physical Neighbors Expand Description